Table of Contents
International Scholarly Research Notices
Volume 2014, Article ID 965235, 9 pages
http://dx.doi.org/10.1155/2014/965235
Review Article

Corticosteroid Treatment Impact on Spinal Deformity in Duchenne Muscular Dystrophy

1Section of Orthopedics and Traumatology, University of Messina, 98125 Messina, Italy
2Laboratory of Musculoskeletal Cell Biology, Rizzoli Orthopedic Institute, IRCCS, 40136 Bologna, Italy
3General Orthopedic Surgery, Rizzoli-Sicilia Department, Rizzoli Orthopedic Institute, Bagheria, 90011 Palermo, Italy

Received 21 June 2014; Accepted 24 August 2014; Published 30 October 2014

Academic Editor: Katherine Athayde Teixeira de Carvalho

Copyright © 2014 Ilaria Sanzarello et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. P. Hoffman, K. H. Fischbeck, R. H. Brown et al., “Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy,” The New England Journal of Medicine, vol. 318, no. 21, pp. 1363–1368, 1988. View at Publisher · View at Google Scholar · View at Scopus
  2. L. M. Kunkel, J. F. Hejtmancik, C. T. Caskey et al., “Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy,” Nature, vol. 322, no. 6074, pp. 73–77, 1986. View at Google Scholar
  3. F. Muntoni, S. Torelli, and A. Ferlini, “Dystrophin and mutations: one gene, several proteins, multiple phenotypes,” The Lancet Neurology, vol. 2, no. 12, pp. 731–740, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Bushby, R. Finkel, D. J. Birnkrant et al., “Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management,” The Lancet Neurology, vol. 9, no. 1, pp. 77–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Eagle, J. Bourke, R. Bullock et al., “Managing Duchenne muscular dystrophy—the additive effect of spinal surgery and home nocturnal ventilation in improving survival,” Neuromuscular Disorders, vol. 17, no. 6, pp. 470–475, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Bushby, R. Finkel, D. J. Birnkrant et al., “Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care,” The Lancet Neurology, vol. 9, no. 2, pp. 177–189, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Ishikawa, T. Miura, Y. Ishikawa et al., “Duchenne muscular dystrophy: survival by cardio-respiratory interventions,” Neuromuscular Disorders, vol. 21, no. 1, pp. 47–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. B. Drachman, K. V. Toyka, and E. Myer, “Prednisone in Duchenne muscular dystrophy,” The Lancet, vol. 2, no. 7894, pp. 1409–1412, 1974. View at Google Scholar · View at Scopus
  9. J. R. Mendell, R. T. Moxley, R. C. Griggs et al., “Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy,” New England Journal of Medicine, vol. 320, no. 24, pp. 1592–1597, 1989. View at Publisher · View at Google Scholar · View at Scopus
  10. R. C. Griggs, R. T. Moxley III, J. R. Mendell et al., “Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months),” Neurology, vol. 43, no. 3, pp. 520–527, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. W. M. King, R. Ruttencutter, H. N. Nagaraja et al., “Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy,” Neurology, vol. 68, no. 19, pp. 1607–1613, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. W. D. Biggar, V. A. Harris, L. Eliasoph, and B. Alman, “Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade,” Neuromuscular Disorders, vol. 16, no. 4, pp. 249–255, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Merlini, M. Gennari, E. Malaspina et al., “Early corticosteroid treatment in 4 duchenne muscular dystrophy patients: 14-year follow-up,” Muscle and Nerve, vol. 45, no. 6, pp. 796–802, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Merlini, “A 19-year-old ambulant Duchenne patient with stunted growth on long-term corticosteroids,” Neuromuscular Disorders, vol. 24, no. 5, pp. 417–418, 2014. View at Publisher · View at Google Scholar
  15. R. T. Moxley III, S. Pandya, E. Ciafaloni, D. J. Fox, and K. Campbell, “Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management,” Journal of Child Neurology, vol. 25, no. 9, pp. 1116–1129, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. E. H. Emery, Duchenne Muscular Dystrophy, Oxford University Press, New York, NY, USA, 1987.
  17. M. Zatz, D. Rapaport, M. Vainzof et al., “Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy,” Journal of the Neurological Sciences, vol. 102, no. 2, pp. 190–196, 1991. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Dubowitz, A Colour Atlas of Muscle Disorders in Childhood, Wolfe Medical Publications, London, UK, 1989.
  19. A. M. Connolly, J. M. Florence, M. M. Cradock et al., “Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network,” Neuromuscular Disorders, vol. 23, no. 7, pp. 529–539, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. R. Mendell and M. Lloyd-Puryear, “Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy,” Muscle & Nerve, vol. 48, no. 1, pp. 21–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Cambridge and J. C. Drennan, “Scoliosis associated with Duchenne muscular dystrophy,” Journal of Pediatric Orthopaedics, vol. 7, no. 4, pp. 436–440, 1987. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Merlini, P. Barile, M. T. Bartone, and C. Granata, “Natural history of Duchenne Muscular Dystrophyes,” in Mechanical Ventilation in Myopathies, A. Gaggi, Ed., pp. 111–127, Istituto Ortopedico Rizzoli, Bologna, Italy, 1989. View at Google Scholar
  23. F. Shapiro, D. Zurakowski, T. Bui, and B. T. Darras, “Progression of spinal deformity in wheelchair-dependent patients with Duchenne muscular dystrophy who are not treated with steroids: coronal plane (scoliosis) and sagittal plane (kyphosis, lordosis) deformity,” The Bone & Joint Journal, vol. 96-B, no. 1, pp. 100–105, 2014. View at Publisher · View at Google Scholar
  24. C. Granata, L. Merlini, S. Cervellati et al., “Long-term results of spine surgery in duchenne muscular dystrophy,” Neuromuscular Disorders, vol. 6, no. 1, pp. 61–68, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Scheuerbrandt, “First meeting of the duchenne parent project in Europe, Rotterdam, The Netherlands, 7-8 November 1997: treatment of Duchenne muscular dystrophy,” Neuromuscular Disorders, vol. 8, no. 3-4, pp. 213–219, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Granata, S. Giannini, L. Rubbini et al., “Orthopedic surgery to prolong walking in Duchenne muscular dystrophy,” La Chirurgia Degli Organi di Movimento, vol. 73, no. 3, pp. 237–248, 1988. View at Google Scholar · View at Scopus
  27. E. B. Rodillo, E. Fernandez-Bermejo, J. Z. Heckmatt, and V. Dubowitz, “Prevention of rapidly progressive scoliosis in Duchenne muscular dystrophy by prolongation of walking with orthoses,” Journal of Child Neurology, vol. 3, no. 4, pp. 269–274, 1988. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Granata, A. de Lollis, G. Campo, L. Piancastelli, and L. Merlini, “Analysis, design and development of a carbon fibre reinforced plastic knee-ankle-foot orthosis prototype for myopathic patients,” Proceedings of the Institution of Mechanical Engineers H: Journal of Engineering in Medicine, vol. 204, no. 2, pp. 91–96, 1990. View at Google Scholar · View at Scopus
  29. D. A. Gibson and K. E. Wilkins, “The management of spinal deformities in Duchenne muscular dystrophy. A new concept of spinal bracing,” Clinical Orthopaedics and Related Research, pp. 41–51, 1975. View at Google Scholar
  30. M. Letts, D. Rathbone, T. Yamashita, B. Nichol, and A. Keeler, “Soft Boston orthosis in management of neuromuscular scoliosis: a preliminary report,” Journal of Pediatric Orthopaedics, vol. 12, no. 4, pp. 470–474, 1992. View at Publisher · View at Google Scholar · View at Scopus
  31. J. D. Hsu and R. Quinlivan, “Scoliosis in Duchenne muscular dystrophy (DMD),” Neuromuscular Disorders, vol. 23, no. 8, pp. 611–617, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Marsh, G. Edge, and J. Lehovsky, “Spinal fusion in patients with Duchenne's muscular dystrophy and a low forced vital capacity,” European Spine Journal, vol. 12, no. 5, pp. 507–512, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Bonnett, J. C. Brown, J. Perry et al., “Evolution of treatment of paralytic scoliosis at Rancho Los Amigos Hospital,” Journal of Bone and Joint Surgery A, vol. 57, no. 2, pp. 206–215, 1975. View at Google Scholar · View at Scopus
  34. P. R. Harrington, “Treatment of scoliosis. Correction and internal fixation by spine instrumentation,” Journal of Bone and Joint Surgery A, vol. 44, pp. 591–610, 1962. View at Google Scholar · View at Scopus
  35. E. R. Luque, “Segmental spinal instrumentation for correction of scoliosis,” Clinical Orthopaedics and Related Research, vol. 163, pp. 192–198, 1982. View at Google Scholar · View at Scopus
  36. R. Arun, S. Srinivas, and S. M. H. Mehdian, “Scoliosis in Duchenne's muscular dystrophy: a changing trend in surgical management: aistorical surgical outcome study comparing sublaminar, hybrid and pedicle screw instrumentation systems,” European Spine Journal, vol. 19, no. 3, pp. 376–383, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. R. L. Weimann, D. A. Gibson, C. F. Moseley, and D. C. Jones, “Surgical stabilization of the spine in Duchenne muscular dystrophy,” Spine, vol. 8, no. 7, pp. 776–780, 1983. View at Publisher · View at Google Scholar · View at Scopus
  38. B. L. Allen Jr. and R. L. Ferguson, “The Galveston technique for L rod instrumentation of the scoliotic spine,” Spine, vol. 7, no. 3, pp. 276–284, 1982. View at Publisher · View at Google Scholar · View at Scopus
  39. K. R. Gurr and P. C. McAfee, “Cotrel-Dubousset instrumentation in adults. A preliminary report,” Spine, vol. 13, no. 5, pp. 510–520, 1988. View at Google Scholar · View at Scopus
  40. P. W. Hitchon, M. D. Brenton, A. G. Black et al., “In vitro biomechanical comparison of pedicle screws, sublaminar hooks, and sublaminar cables,” Journal of Neurosurgery, vol. 99, no. 1, pp. 104–109, 2003. View at Google Scholar · View at Scopus
  41. Y. J. Kim, L. G. Lenke, J. Kim et al., “Comparative analysis of pedicle screw versus hybrid instrumentation in posterior spinal fusion of adolescent idiopathic scoliosis,” Spine, vol. 31, no. 3, pp. 291–298, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Labarque, K. Freson, C. Thys et al., “Increased Gs signalling in platelets and impaired collagen activation, due to a defect in the dystrophin gene, result in increased blood loss during spinal surgery,” Human Molecular Genetics, vol. 17, no. 3, pp. 357–366, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Gayraud, M. Ramonatxo, F. Rivier, V. Humberclaude, B. Petrof, and S. Matecki, “Ventilatory parameters and maximal respiratory pressure changes with age in duchenne muscular dystrophy patients,” Pediatric Pulmonology, vol. 45, no. 6, pp. 552–559, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. J. D. Kennedy, A. J. Staples, P. D. Brook et al., “Effect of spinal surgery on lung function in Duchenne muscular dystrophy,” Thorax, vol. 50, no. 11, pp. 1173–1178, 1995. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Shapiro, D. Zurakowski, and N. F. Sethna, “Tranexamic acid diminishes intraoperative blood loss and transfusion in spinal fusions for duchenne muscular dystrophy scoliosis,” Spine, vol. 32, no. 20, pp. 2278–2283, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Miller, C. F. Moseley, and J. Koreska, “Spinal fusion in Duchenne muscular dystrophy,” Developmental Medicine and Child Neurology, vol. 34, no. 9, pp. 775–786, 1992. View at Google Scholar · View at Scopus
  47. I. Gill, M. Eagle, J. S. Mehta, M. J. Gibson, K. Bushby, and R. Bullock, “Correction of neuromuscular scoliosis in patients with preexisting respiratory failure,” Spine, vol. 31, no. 21, pp. 2478–2483, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. R. T. Moxley III, S. Ashwal, S. Pandya et al., “Practice parameter: corticosteroid treatment of Duchenne dystrophy—report of the quality standards subcommittee of the American academy of neurology and the practice committee of the child neurology society,” Neurology, vol. 64, no. 1, pp. 13–20, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Sansome, P. Royston, and V. Dubowitz, “Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule,” Neuromuscular Disorders, vol. 3, no. 5-6, pp. 567–569, 1993. View at Publisher · View at Google Scholar · View at Scopus
  50. G. T. Carter and C. M. McDonald, “Preserving function in Duchenne dystrophy with long-term pulse prednisone therapy,” American Journal of Physical Medicine and Rehabilitation, vol. 79, no. 5, pp. 455–458, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. A. M. Connolly, J. Schierbecker, R. Renna, and J. Florence, “High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy,” Neuromuscular Disorders, vol. 12, no. 10, pp. 917–925, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Merlini, A. Cicognani, E. Malaspina et al., “Early prednisone treatment in Duchenne muscular dystrophy,” Muscle and Nerve, vol. 27, no. 2, pp. 222–227, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Angelini, “The role of corticosteroids in muscular dystrophy: a critical appraisal,” Muscle and Nerve, vol. 36, no. 4, pp. 424–435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Takagi, T. Watanabe, S. Kojima, and Y. Endo, “Effect of long-term administration of prednisolone on serum creatine kinase and muscle pathology of mdx mouse,” Clinical Neurology, vol. 38, no. 8, pp. 724–728, 1998. View at Google Scholar · View at Scopus
  55. L. Metzinger, A.-C. Passaquin, W. J. Leijendekker, P. Poindron, and U. T. Ruegg, “Modulation by prednisolone of calcium handling in skeletal muscle cells,” British Journal of Pharmacology, vol. 116, no. 7, pp. 2811–2816, 1995. View at Publisher · View at Google Scholar · View at Scopus
  56. A.-C. Passaquin, P. Lhote, and U. T. Rüegg, “Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells,” British Journal of Pharmacology, vol. 124, no. 8, pp. 1751–1759, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. F. Muntoni, I. Fisher, J. E. Morgan, and D. Abraham, “Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research,” Neuromuscular Disorders, vol. 12, supplement 1, pp. S162–S165, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. B. Cai, M. J. Spencer, G. Nakamura, L. Tseng-Ong, and J. G. Tidball, “Eosinophilia of dystrophin-deficient muscle is promoted by perforin-mediated cytotoxicity by T cell effectors,” The American Journal of Pathology, vol. 156, no. 5, pp. 1789–1796, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. J. E. Anderson, M. Weber, and C. Vargas, “Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy,” Cell Transplantation, vol. 9, no. 4, pp. 551–564, 2000. View at Google Scholar · View at Scopus
  60. S. Kojima, A. Takagi, and T. Watanabe, “Effect of prednisolone on apoptosis and cellular infiltration in mdx mouse muscle,” Clinical Neurology, vol. 39, no. 11, pp. 1109–1113, 1999. View at Google Scholar · View at Scopus
  61. S. C. J. M. Jacobs, A. L. Bootsma, P. W. A. Willems, P. R. Bär, and J. H. Wokke, “Prednisone can protect against exercise-induced muscle damage,” Journal of Neurology, vol. 243, no. 5, pp. 410–416, 1996. View at Publisher · View at Google Scholar · View at Scopus
  62. L. McIntosh, K. E. Granberg, K. M. Briere, and J. E. Anderson, “Nuclear magnetic resonance spectroscopy study of muscle growth, mdx dystrophy and glucocorticoid treatments: correlation with repair,” NMR in Biomedicine, vol. 11, pp. 1–10, 1998. View at Google Scholar
  63. A. Gaud, J.-M. Simon, T. Witzel, M. Carre-Pierrat, C. G. Wermuth, and L. Ségalat, “Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans,” Neuromuscular Disorders, vol. 14, no. 6, pp. 365–370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. S. J. G. St-Pierre, J. V. Chakkalakal, S. M. Kolodziejczyk, J. C. Knudson, B. J. Jasmin, and L. A. Megeney, “Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway,” The FASEB Journal, vol. 18, no. 15, pp. 1937–1939, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. V. Guerriero Jr. and J. R. Florini, “Dexamethasone effects on myoblast proliferation and differentiation,” Endocrinology, vol. 106, no. 4, pp. 1198–1202, 1980. View at Publisher · View at Google Scholar · View at Scopus
  66. A. C. Passaquin, L. Metzinger, J. J. Leger, J.-M. Warter, and P. Poindron, “Prednisolone enhances myogenesis and dystrophin-related protein in skeletal muscle cell cultures from mdx mouse,” Journal of Neuroscience Research, vol. 35, no. 4, pp. 363–372, 1993. View at Publisher · View at Google Scholar · View at Scopus
  67. F. Pasquini, C. Guerin, D. Blake, K. Davies, G. Karpati, and P. Holland, “The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells,” Neuromuscular Disorders, vol. 5, no. 2, pp. 105–114, 1995. View at Publisher · View at Google Scholar · View at Scopus
  68. Z. Rifai, S. Welle, R. T. Moxley III, M. Lorenson, and R. C. Griggs, “Effect of prednisone on protein metabolism in Duchenne dystrophy,” The American Journal of Physiology, vol. 268, no. 1, pp. E67–E74, 1995. View at Google Scholar · View at Scopus
  69. H. Kawai, K. Adachi, Y. Nishida, T. Inui, C. Kimura, and S. Saito, “Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment,” Journal of Neurology, vol. 240, no. 3, pp. 181–186, 1993. View at Publisher · View at Google Scholar · View at Scopus
  70. O. Hardiman, R. M. Sklar, and R. H. Brown Jr., “Methylprednisolone selectively affects dystrophin expression in human muscle cultures,” Neurology, vol. 43, no. 2, pp. 342–345, 1993. View at Publisher · View at Google Scholar · View at Scopus
  71. R. M. Sklar and R. H. Brown Jr., “Methylprednisolone increases dystrophin levels by inhibiting myotube death during myogenesis of normal human muscle in vitro,” Journal of the Neurological Sciences, vol. 101, no. 1, pp. 73–81, 1991. View at Publisher · View at Google Scholar · View at Scopus
  72. M. R. A. Hussein, E. E. Abu-Dief, N. F. Kamel, and M. G. Mostafa, “Steroid therapy is associated with decreased numbers of dendritic cells and fibroblasts, and increased numbers of satellite cells, in the dystrophic skeletal muscle,” Journal of Clinical Pathology, vol. 63, no. 9, pp. 805–813, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. J. T. Kissel, D. J. Lynn, K. W. Rammohan et al., “Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy,” Neurology, vol. 43, no. 3, pp. 532–536, 1993. View at Publisher · View at Google Scholar · View at Scopus
  74. R. Quinlivan, N. Shaw, and K. Bushby, “170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27-29 November 2009, Naarden, The Netherlands,” Neuromuscular Disorders, vol. 20, no. 11, pp. 761–769, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. D. E. Lebel, J. A. Corston, L. C. McAdam, W. D. Biggar, and B. A. Alman, “Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up,” The Journal of Bone and Joint Surgery A, vol. 95, no. 12, pp. 1057–1061, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. A. M. Connolly, H. J. Kim, and K. H. Bridwell, “Corticosteroids can reduce the severity of scoliosis in Duchenne muscular dystrophy,” The Journal of Bone and Joint Surgery. American Volume, vol. 95, no. 12, article e86, 2013. View at Google Scholar · View at Scopus
  77. J. M. Dooley, K. E. Gordon, and J. M. MacSween, “Impact of steroids on surgical experiences of patients with duchenne muscular dystrophy,” Pediatric Neurology, vol. 43, no. 3, pp. 173–176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Houde, M. Filiatrault, A. Fournier et al., “Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up,” Pediatric Neurology, vol. 38, no. 3, pp. 200–206, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. L. C. McAdam, A. L. Mayo, B. A. Alman, and W. D. Biggar, “The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy,” Acta Myologica, vol. 31, pp. 16–20, 2012. View at Google Scholar
  80. B. A. Alman, S. N. Raza, and W. D. Biggar, “Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy,” The Journal of Bone and Joint Surgery A, vol. 86, no. 3, pp. 519–524, 2004. View at Google Scholar · View at Scopus
  81. W. D. Biggar, M. Gingras, D. L. Fehlings, V. A. Harris, and C. A. Steele, “Deflazacort treatment of Duchenne muscular dystrophy,” The Journal of Pediatrics, vol. 138, no. 1, pp. 45–50, 2001. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Kinali, M. Main, J. Eliahoo et al., “Predictive factors for the development of scoliosis in Duchenne muscular dystrophy,” European Journal of Paediatric Neurology, vol. 11, no. 3, pp. 160–166, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. B. Balaban, D. J. Matthews, G. H. Clayton, and T. Carry, “Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy long-term effect,” The American Journal of Physical Medicine and Rehabilitation, vol. 84, no. 11, pp. 843–850, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. A. S. Daftary, M. Crisanti, M. Kalra, B. Wong, and R. Amin, “Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy,” Pediatrics, vol. 119, no. 2, pp. e320–e324, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. D. L. MacHado, E. C. Silva, M. B. Resende, C. R. F. Carvalho, E. Zanoteli, and U. C. Reed, “Lung function monitoring in patients with duchenne muscular dystrophy on steroid therapy,” BMC Research Notes, vol. 5, article 435, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. E. P. Hoffman and E. M. McNally, “Exon-skipping therapy: a roadblock, detour, or bump in the road?” Science Translational Medicine, vol. 6, Article ID 230fs14, 2014. View at Publisher · View at Google Scholar
  87. E. P. Hoffman and E. M. Connor, “Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies,” Discovery Medicine, vol. 16, pp. 233–239, 2013. View at Google Scholar
  88. Q. L. Lu, S. Cirak, and T. Partridge, “What can we learn from clinical trials of exon skipping for DMD?” Molecular Therapy—Nucleic Acids, vol. 3, Article ID e152, 2014. View at Publisher · View at Google Scholar